2.4. Analysis.
Comparison 2: Exenatide vs no treatment (14 months (60.8 weeks) post baseline), Outcome 4: Adverse events ‐ weight loss (kg) (assessed at 12 months (52 weeks))
Comparison 2: Exenatide vs no treatment (14 months (60.8 weeks) post baseline), Outcome 4: Adverse events ‐ weight loss (kg) (assessed at 12 months (52 weeks))